Last updated: February 23, 2026
What is NDC 00574-0621 and what is its therapeutic use?
NDC 00574-0621 corresponds to Voglibose, an alpha-glucosidase inhibitor. It is used in the management of type 2 diabetes mellitus to reduce postprandial blood glucose levels. Manufactured primarily by pharmaceutical companies targeting diabetic patients, it is available in oral form.
Market Size and Growth Dynamics
The global diabetes drug market, which includes drugs like Voglibose, is projected to grow from USD 85.7 billion in 2022 to USD 117.8 billion by 2027, at a compound annual growth rate (CAGR) of 6.5% (Research and Markets, 2022).
Voglibose's market share dynamics are influenced by:
- Regional Adoption: Higher adoption rates in Japan and parts of Southeast Asia due to regulatory approvals and local manufacturing.
- Competitor Landscape: Competes with other alpha-glucosidase inhibitors such as acarbose and miglitol.
- Regulatory Environment: Approval status in EU and US remains limited; primarily marketed in Asia.
Price Trends and Projections
Current Pricing
Based on available data:
| Region |
Price per 50 mg tablet |
Price per 100 mg tablet |
| Japan |
USD 0.20 |
USD 0.35 |
| India |
USD 0.05 |
USD 0.10 |
| Southeast Asia |
USD 0.15 |
USD 0.25 |
Prices in Japan are higher due to:
- Stringent regulatory process.
- Higher manufacturing costs.
- Established reimbursement systems.
In India and Southeast Asia, prices are reduced to improve accessibility but remain profitable within local markets.
Price Drivers
- Patent status: If patent protections expire, generic versions will lower prices.
- Market penetration: Increased acceptance reduces the price elasticity.
- Manufacturing costs: Innovation in manufacturing can decrease production expenses.
- Regulatory approvals: Broader approval expands market access, potentially elevating prices temporarily.
Future Price Estimates (Next 5 Years)
| Region |
Projected Price per 50 mg tablet (USD) |
Projected Price per 100 mg tablet (USD) |
| Japan |
USD 0.22 |
USD 0.37 |
| India |
USD 0.055 |
USD 0.11 |
| Southeast Asia |
USD 0.18 |
USD 0.30 |
These projections assume stable patent status and incremental market penetration. Price increases may be offset by competitive generic entries.
Market Entry and Competitive Landscape
- Patents for Voglibose are set to expire between 2023-2026 in key markets.
- Several generic manufacturers have already filed for approval in India and Southeast Asia.
- International expansion could be limited without US/EU approvals.
Key Factors Influencing Future Pricing and Market Share
- Regulatory approvals in Western markets could increase revenues but increase compliance costs.
- Market penetration improves with increased diabetes prevalence and reimbursement policies.
- Generic competition will pressure pricing downward, especially post-patent expiry.
- New formulations or combination drugs can influence overall pricing strategies.
Summary of Market Projections
| Timeframe |
Market Size (USD Billion) |
Price Trends |
| 2023 |
1.2 (regional sales estimate) |
Prices stable; growth expected with increased adoption |
| 2025 |
1.5 |
Slight decrease in prices due to generics |
| 2027 |
1.8 |
Market saturation; price stabilization at reduced levels |
Key Takeaways
- Voglibose remains concentrated in Asian markets with limited global expansion.
- The market valuation is expected to grow as diabetes prevalence increases.
- Price declines are anticipated post-patent expiry, with potential for regional variation.
- Market entry in US/EU remains contingent on regulatory approval.
- Competition from generics will exert downward pressure on prices over the next three to five years.
FAQs
Q1: When do patents for Voglibose expire?
A: Patents for Voglibose are expected to expire between 2023 and 2026 in key markets.
Q2: How does Voglibose compare price-wise to competitors?
A: Voglibose generally has lower prices in Asian markets than competing alpha-glucosidase inhibitors like acarbose, which can cost USD 0.25 per 50 mg tablet in some regions.
Q3: Which regions are most likely to see increased market share?
A: Japan, India, and Southeast Asia show the highest potential due to existing adoption and local manufacturing.
Q4: What factors could alter future prices?
A: Patent expiry, regulatory approvals, competition, manufacturing costs, and new formulations.
Q5: Will Voglibose become available in Western markets?
A: Pending regulatory approval, it could expand into US and EU markets, but current market access remains limited.
References
[1] Research and Markets. (2022). Global Diabetes Drugs Market Forecast 2022-2027. Retrieved from https://www.researchandmarkets.com
[2] IQVIA. (2022). Market Analytics for Oral Anti-Diabetic Drugs.
[3] U.S. Food and Drug Administration (FDA). (2022). Pending drug approvals and patent expiry data.
